This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CDMO Avid Bioservices (CDMO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Avid Bioservices Stock (NASDAQ:CDMO) Get Avid Bioservices alerts:Sign Up Key Stats Today's Range$12.47▼$12.5150-Day Range$12.50▼$12.5052-Week Range$8.74▼$12.51Volume3.07 million shsAverage Volume1.45 million shsMarket Capitalization$799.18 millionP/E RatioN/ADividend YieldN/APrice Target$12.50Consensus RatingHold Company Overview Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California. Read More Avid Bioservices Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreCDMO MarketRank™: Avid Bioservices scored higher than 15% of companies evaluated by MarketBeat, and ranked 891st out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingAvid Bioservices has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Avid Bioservices is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAvid Bioservices has received no research coverage in the past 90 days.Read more about Avid Bioservices' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Avid Bioservices are expected to grow in the coming year, from ($0.46) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avid Bioservices is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avid Bioservices is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvid Bioservices has a P/B Ratio of 4.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CDMO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvid Bioservices does not currently pay a dividend.Dividend GrowthAvid Bioservices does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-0.96 Short InterestThere is no current short interest data available for CDMO. News and Social MediaN/ANews SentimentN/A Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Avid Bioservices insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.05% of the stock of Avid Bioservices is held by insiders.Percentage Held by Institutions97.16% of the stock of Avid Bioservices is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avid Bioservices' insider trading history. Receive CDMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CDMO Stock News HeadlinesDr. Park CDMO Selects Thermo Fisher Scientific to Equip New Viral Vector Manufacturing FacilitySeptember 24, 2025 | businesswire.comTEHN.BE,0P0000CK2E,0 (TEHN.BE)July 2, 2025 | finance.yahoo.comThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the verge of its biggest breakthrough yet — a revolutionary form of “Manifested AI” that Forbes has called a multi-trillion-dollar opportunity, potentially sparking a 25,000% growth market and setting up what he believes could be the greatest corporate comeback in history. | Brownstone Research (Ad)Avid Bioservices launches new company website designFebruary 10, 2025 | markets.businessinsider.comAvid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor ExperienceFebruary 10, 2025 | globenewswire.comGHO Capital, Ampersand Capital announce closing of Avid Bioservices acquisitionFebruary 5, 2025 | markets.businessinsider.comAvid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed MergerFebruary 5, 2025 | globenewswire.comAvid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital PartnersFebruary 5, 2025 | globenewswire.comSee More Headlines CDMO Stock Analysis - Frequently Asked Questions How were Avid Bioservices' earnings last quarter? Avid Bioservices, Inc. (NASDAQ:CDMO) issued its earnings results on Tuesday, December, 10th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.14. Avid Bioservices had a negative net margin of 101.07% and a negative trailing twelve-month return on equity of 33.18%. When did Avid Bioservices' stock split? Avid Bioservices shares reverse split on the morning of Monday, July 10th 2017.The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of Avid Bioservices own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avid Bioservices investors own include American Water Works (AWK), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and Humana (HUM). Company Calendar Last Earnings12/10/2024Today10/13/2025Fiscal Year End4/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CDMO CIK704562 Webwww.avidbio.com Phone(714) 508-6100Fax714-838-5817Employees320Year Founded1981Price Target and Rating Average Price Target for Avid Bioservices$12.50 High Price Target$12.50 Low Price Target$12.50 Potential Upside/Downside+0.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($2.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$140.75 million Net Margins-101.07% Pretax MarginN/A Return on Equity-33.18% Return on Assets-8.45% Debt Debt-to-Equity Ratio3.58 Current Ratio1.30 Quick Ratio0.92 Sales & Book Value Annual Sales$139.91 million Price / Sales5.71 Cash Flow$0.15 per share Price / Cash Flow80.92 Book Value$3.02 per share Price / Book4.14Miscellaneous Outstanding Shares63,960,000Free Float62,012,000Market Cap$799.18 million OptionableOptionable Beta1.39 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CDMO) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneInvestors are quietly piling into this secret AI stock Elon hates… It's one of those things you just need t...Economic Media | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avid Bioservices, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avid Bioservices With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
